Centocor and Schering-Plough's Simponi gains first approval
14 April 2009
Katie McQue
Please Login to read the full article.
14 April 2009
Katie McQue
Centocor ( Johnson & Johnson) and Schering-Plough's fully humanised anti-TNF therapy Simponi (golimumab), a once-monthly subcutaneous injection, has received marketing approval in Canada, its first market.
It is indicated for the treatment of moderate-to-severe rheumatoid arthritis...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Janssen seeks FDA meeting to discuss Simponi complete response
- SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
- NICE green light helps Merck offer RA patients wider treatment choice
- MTP looks to Simponi to secure dominant rheumatoid arthritis position in Japan
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
